JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan has maintained a Market Outperform rating on Benitec Biopharma (NASDAQ:BNTC) and raised the price target from $10 to $16.
April 22, 2024 | 4:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has maintained a Market Outperform rating on Benitec Biopharma and increased the price target from $10 to $16.
The upgrade in price target by JMP Securities reflects a positive outlook on Benitec Biopharma's future performance. This is likely to generate investor optimism and could lead to a short-term increase in the stock price, given the analyst's bullish stance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100